Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bar

Showing results (161-170 of 168) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 168 results.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Heredity|June 3, 2005
Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesusJ Hillel, D Gefel, R Kalman, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
Pageof 17

Showing results (161-170 of 168) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 168 results.
Alimentary Pharmacology & Therapeutics|November 11, 2017
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapyH Bar-Yoseph, N Levhar, L Selinger, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 1, 1991
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaK A Margolin, F R Aronson, M Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1990
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimenD R Parkinson, R I Fisher, A A Rayner, et al.
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Heredity|June 3, 2005
Evidence for a major gene affecting the transition from normoglycaemia to hyperglycaemia in Psammomys obesusJ Hillel, D Gefel, R Kalman, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
Pageof 17